In vitro evaluation of G1: A novel antimicrobial compound

International Journal of Antimicrobial Agents

Volumn 11, Issue 2, 1999, Pages 163-166

  Blondeau, J M ^a,b   Castanedo, N ^a   Gonzalez, O ^a   Mendina, R ^a   Silveira, E ^a  

^a CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Antimicrobial; G1; In vitro evaluation

Indexed keywords

1 (5 BROMO 2 FURYL) 2 BROMO 2 NITROETHENE; ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTICLE; ASPERGILLUS; BACTEROIDES FRAGILIS; CANDIDA ALBICANS; DERMATOPHYTE; ENTEROBACTER; ESCHERICHIA COLI; FUSARIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LISTERIA; MICROSPORUM CANIS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; YEAST;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; FUNGI; FURANS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS;

EID: 0033044283     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00086-7     Document Type: Article

References (12)

1. Blondeau JM, Yaschuk Y. In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis. Antimicrob Agents Chemother 1995;39:2577-9.
2. The Canadian Ciprofloxacin Study Group, Blondeau JM, Yaschuk Y. Canadian ciprofloxacin susceptibility study: a comparative study from 15 medical centers. Antimicrob Agents Chemother 1996;40:1729-32.
3. The Canadian Multicenter Study Group, Blondeau JM, Yaschuk Y. Canadian multicenter susceptibility study, with a focus on cephalosporins, from 15 Canadian medical centers. Antimicrob Agents Chemother 1997;41:2773-5.
4. Blondeau JM, Shiplett ME, The Canadian Study Group. Canadian Pseudomonas aeruginosa susceptibility study: a comparative study from 55 Canadian centers. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstract #E12.
5. National Committee for Clinical Laboratory Standards. Approved Standard M7-A2. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
6. National Committee for Clinical Laboratory Standards. Approved Standard M11-A2. Methods for antimicrobial susceptibility testing of anaerobic bacteria, National Committee for Clinical Laboratory Standards, Villanova, PA, 1993.
7. National Committee for Clinical Laboratory Standards. Approved Standard M27-T. Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standard. National Committee for Clinical Laboratory Standards, Villanova, PA, 1995.
8. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30254 aerobic and anaerobic pathogens isolated world wide. Diagn Microbiol Infect Dis 1997;28:157-63.
9. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibilities of 394 Bacteroides fragilis, Non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother 1991;35:1214-8.
10. McGinnis MR, Rinaldi MG. Antifungal drugs: Mechanisms of action, drug ressistance, susceptibility testing, and assays of activity in biologic fluids. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore: Williams and Wilkins, 1996:176-211.
11. Petranyi G, Meingassner JG, Hubert M. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987;31:1365-5.
12. Clayton YM. In vitro activity of terbinafine. Clin Experimen Dermatol 1989;14:101-3.